COMMUNIQUÉS West-GlobeNewswire
-
INmune Bio Inc Issues Shareholder Letter Reviewing 2025 Milestones and Outlining 2026 Strategic Initiatives
27/01/2026 -
Amneal to Report Fourth Quarter and Full Year 2025 Results on February 27, 2026
27/01/2026 -
Evosep Launches IQ/OQ Protocols for the Evosep Eno System at WCBP 2026
27/01/2026 -
First Steroid Cycle for Bodybuilders – CrazyBulk | Steroids for Beginners Bulking and Cutting: Safest Steroids for Bodybuilding
27/01/2026 -
Propanc Biopharma Accelerates IP Momentum: Files Fourth Provisional Patent Application in Just Two Months – Strengthening Global Protection for Breakthrough Proenzyme Formulations
27/01/2026 -
Bluejay Diagnostics Announces 1-for-4 Reverse Stock Split
27/01/2026 -
TG Therapeutics Announces Schedule of Data Presentations for BRIUMVI® (ublituximab) in Multiple Sclerosis at the Americas Committee for Treatment and Research in Multiple Sclerosis Annual Forum
27/01/2026 -
Will Forte Teams Up with Teva to Get Real About Huntington’s Disease with ‘Honestly HD’
27/01/2026 -
PreatLoc™ by Preat® is Now Available
27/01/2026 -
Bicycle Health Appoints Rick Dean as Chief Executive Officer to Lead Next Phase of Growth
27/01/2026 -
Zymeworks Announces Participation in Upcoming Investor Conferences
27/01/2026 -
Greenwich LifeSciences Provides Update on FLAMINGO-01 Cash Burn Rate and Financing Strategy
27/01/2026 -
Aclaris Therapeutics’ Novel ITK/JAK3 Inhibitor ATI-2138 Demonstrates Rapid and Sustained Hair Regrowth in Validated Murine Model of Alopecia Areata (AA)
27/01/2026 -
Sevaro Health Expands Leadership Team with Key Appointments
27/01/2026 -
Cardiff Oncology Announces Executive Leadership Changes as it Transitions to Late-Stage Clinical Development
27/01/2026 -
SweetWater 420 Fest Unveils Powerhouse 2026 Lineup: Umphrey’s McGee, Thievery Corporation & Chromeo to Headline
27/01/2026 -
Evestia Clinical Acquires ICRC-Weyer to Enhance Global Full-Service Clinical Research Capabilities
27/01/2026 -
Opus Genetics Launches Gene Therapy Clinical Trial for MERTK-related Retinitis Pigmentosa
27/01/2026 -
Transpire Bio’s ANDA for Generic Trelegy® Ellipta® Accepted for Filing by the U.S. FDA
27/01/2026
Pages